RIBT's Price/Sales is .39. It is calculated by the price of .07 divided by the revenue per share on an annual basis or $37,000,000 divided by 207,000,000 or about .1787. That figure is .39. It is tough to figure companies business, exactly but here is a list of sort of comparable companies
CALM--.96
HNZ -1.61
HAIN-1.92
SNAK .66
THS .89
CAG .90

Average 1.16.

If RIBT is co compare to the average, the stock should be selling at .208. Of course other factors figure in on valuation like earnings. But for an example, HSH which I recently posted on has a Price/Sales of .84. That is the reason it is a takeover target given in the article. Now add in the fact that Irgovel in less than 6 months will be doing 50% more sales and at a higher margin. Beneo could raise the stateside 50% as well, they we got a new area, nutraceuticals that could really rocket sales.

With what is coming, I believe RIBT should have HAIN's Price/Sales ration of 1.92.,, IMO. Or RIBT stock should be going for $.345 per share, TODAY.